deltatrials
Completed PHASE3 NCT04169373

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects With Axial Spondyloarthritis Followed by a Remission-Withdrawal Period

Sponsor: AbbVie

Updated 27 times since 2019 Last updated: Feb 6, 2026 Started: Nov 26, 2019 Primary completion: Sep 2, 2021 Completion: Feb 28, 2025

This PHASE3 trial investigates Spondyloarthritis and is currently completed. AbbVie leads this study, which shows 27 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

27 versions recorded
  1. Feb 2026 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE3

  3. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  4. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

Show 22 earlier versions
  1. Jun 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  2. May 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Dec 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Nov 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  6. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  8. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  9. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  10. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  11. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  12. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  13. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  14. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  15. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  16. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  17. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  18. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  19. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  20. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  21. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  22. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

    First recorded

Nov 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Armthorpe Road, United Kingdom, Asahikawa-shi, Japan, Austin, United States, Aventura, United States, Baotou, China, Beckley, United States, Beijing, China, Bengbu, China, Berlin, Germany, Bialystok, Poland and 168 more location s